Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment,...

Sensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence Keloid recurrence rate of 10.4% at 12 months for patients treated with SRT following keloidectomy compares with more than 80% with surgical excision aloneRetrospective study published in Journal of...

American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems BOCA RATON, Fla, Aug. 05, 2020 (GLOBE NEWSWIRE) -- ...

Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and...

Evidence-Based Guidelines Issued by ASTRO Support Sensus Healthcare’s SRT Technology as the First-Line Alternative to Surgery for Treating Non-Melanoma Skin Cancer Influential professional organization recommends radiotherapy as the primary non-surgical alternative for patients with basal cell or cutaneous squamous cell carcinomas BOCA RATON, Fla, July 14,...